"The response to this initiative has been very poor; only 57 votes in 2 weeks. Quite depressing really!!"
"I am really not sure if the repurposing of off-patent drugs for MS is such a good idea after all. May be we should just maintain the status quo and let Big Pharma do what it does best; develop patented drugs under the current regulatory framework? This also raises ethical questions about whether or not we should be wasting precious resources on investigating off-patent drugs in MS if we don't have the mechanism to get them through a phase 3 program and then licensed. The latter is essential for adoption."
"I am really not sure if the repurposing of off-patent drugs for MS is such a good idea after all. May be we should just maintain the status quo and let Big Pharma do what it does best; develop patented drugs under the current regulatory framework? This also raises ethical questions about whether or not we should be wasting precious resources on investigating off-patent drugs in MS if we don't have the mechanism to get them through a phase 3 program and then licensed. The latter is essential for adoption."
"I will leave the poll open to see if we can garner any further support!"
Previous post on the BPA:
29 Nov 2012;
With the current level of risk associated with drug development and the level of regulatory red-tape it seems unlikely. Even Big Pharma themselves are having second thoughts about the current paradigm and trying new things ...
0 comments:
Post a Comment